Sign in
Active, not recruitingPhase 1

GDNF Gene Therapy for Multiple System Atrophy

Key facts

Who runs it
Brain Neurotherapy Bio, Inc.
Where
Boca Raton, Boston, Columbus, Farmington Hills, Irvine, Nashville, and New York, United StatesSee the 7 sites
Trial code
Status
Active, not recruiting
Phase
Phase 1
People taking part
9 people, planned
Started
3 Oct 2023
Expected to end
Aug 2028
Type of study
Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
Treatments tested
  • AAV2-GDNF gene therapy
  • Sham (Placebo) Surgery
Record updated
30 January 2026

Who can take part

Age
35 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Male and female 35-75 years of age (inclusive)
  • Clinical diagnosis of MSA, parkinsonian type with symptoms onset sporadic, progressive and > 30 years of age
  • Less than 5 years from MSA parkinsonian diagnosis with expected survival more than 3 years
  • Stable anti-parkinsonian medication regimen
  • Ability to walk a distance of 25 feet with or without an assistive device

Who cannot take part

  • Prior brain surgery (i.e., deep brain stimulator implantation) or other brain imaging abnormalities
  • Received investigational agent within 12 weeks
  • Presence of idiopathic Parkinson's disease (PD) or any PD-related mutation or other neurological diseases
  • Presence of dementia, psychosis, substance abuse or poorly controlled depression
  • History of cancer or poorly controlled medical conditions that would increase surgical risk
  • Inability to tolerate laying flat in an MRI and/or allergy to gadolinium; NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

Where in United States

  • Parkinson's Disease and Movement Disorders Center of Boca RatonBoca Raton, United States
  • Massachusetts General HospitalBoston, United States
  • The Ohio State University Medical CenterColumbus, United States
  • QUEST Research InstituteFarmington Hills, United States
  • University of California, IrvineIrvine, United States
  • Vanderbilt University Medical CenterNashville, United States
  • NYU Langone HealthNew York, United States

About the trial

What the trial wants to find out

The objective of this randomized, double-blinded, placebo-controlled Phase 1 investigation is to evaluate the safety and potential clinical effect of AAV2-GDNF delivered to the putamen in subjects with either a possible or probable diagnosis of Multiple System Atrophy.

The 2 groups in the trial

  • Active TreatmentTreatment being tested

    Treatment: AAV2-GDNF gene therapy

  • Placebo SurgerySham treatment, for comparison

    Treatment: Sham (Placebo) Surgery

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Randomized, Double-Blind, Placebo-controlled Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2-GDNF) in Multiple System Atrophy
Record updated
30 January 2026